Compare ENR & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENR | PHAR |
|---|---|---|
| Founded | 2015 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2015 | 2020 |
| Metric | ENR | PHAR |
|---|---|---|
| Price | $18.77 | $17.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | $24.71 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 1.1M | 17.3K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.49% | N/A |
| EPS Growth | ★ 538.46 | N/A |
| EPS | ★ 3.32 | N/A |
| Revenue | ★ $2,952,700,000.00 | N/A |
| Revenue This Year | $4.51 | $10.04 |
| Revenue Next Year | $1.07 | $2.51 |
| P/E Ratio | ★ $5.57 | $3,041.22 |
| Revenue Growth | ★ 2.28 | N/A |
| 52 Week Low | $16.00 | $8.00 |
| 52 Week High | $30.29 | $21.34 |
| Indicator | ENR | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 58.84 | 59.90 |
| Support Level | $16.38 | $15.72 |
| Resistance Level | $21.62 | $17.60 |
| Average True Range (ATR) | 0.63 | 0.64 |
| MACD | 0.38 | 0.15 |
| Stochastic Oscillator | 94.67 | 83.41 |
Energizer Holdings Inc. manufactures and distributes household batteries, specialty batteries, and lighting products. The company offers batteries using lithium, alkaline, carbon zinc, nickel metal hydride, zinc air, and silver oxide technologies, sold under the Energizer, Rayovac, Varta, and Eveready brands across performance and premium price segments. It also provides auto care products in the appearance, fragrance, performance, and air conditioning recharge categories. Energizer operates through two geographical segments, the United States and International, with the majority of its revenue generated in the United States. It has two product segments: Batteries and Lights and Auto Care, with the Batteries and Lights segment contributing the majority of its revenue.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.